-
1.
公开(公告)号:US20150174124A1
公开(公告)日:2015-06-25
申请号:US14635635
申请日:2015-03-02
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: A61K31/496
CPC分类号: A61K31/496 , A61K9/0053 , A61K45/06 , C07B2200/13 , C07D261/20 , Y02A50/414 , A61K2300/00
摘要: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
摘要翻译: 本发明涉及4 - ((3-(4-环己基哌嗪-1-基)-6-氧代-6H-蒽[1,9-cd]异恶唑-5-基)氨基)的各种多晶型和无定形形式。 苯甲酸盐,包括多晶型物A,多晶型物的混合物,其制备方法及其在含有它们的药物组合物中的用途。
-
公开(公告)号:US20140228331A1
公开(公告)日:2014-08-14
申请号:US14256094
申请日:2014-04-18
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: C07D261/20 , A61K31/496 , A61K45/06
CPC分类号: C07D498/06 , A61K31/496 , A61K31/497 , A61K45/06 , C07D215/20 , C07D221/06 , C07D223/32 , C07D241/44 , C07D261/20 , C07D265/36 , C07D279/16 , C07D295/13 , C07D307/77 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D493/06 , C07D495/04 , C07D498/04 , C07D513/04
摘要: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
摘要翻译: 本发明涉及新型合成取代的杂环化合物和含有能够抑制或拮抗受体酪氨酸激酶家族(Tropomysosin Related Kinases,Trk),特别是神经生长因子(NGF)受体TrkA的家族的合成取代的杂环化合物和药物组合物。 本发明还涉及这些化合物在治疗和/或预防疼痛,癌症,再狭窄,动脉粥样硬化,牛皮癣,血栓形成或与异常髓鞘或脱髓鞘有关的疾病,病症或损伤或与异常活动有关的疾病或病症 的NGF受体TrkA。
-
公开(公告)号:US08999992B2
公开(公告)日:2015-04-07
申请号:US14208244
申请日:2014-03-13
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: A61K31/495 , C07D261/20
CPC分类号: A61K31/496 , A61K9/0053 , A61K45/06 , C07B2200/13 , C07D261/20 , Y02A50/414 , A61K2300/00
摘要: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
摘要翻译: 本发明涉及4 - ((3-(4-环己基哌嗪-1-基)-6-氧代-6H-蒽[1,9-cd]异恶唑-5-基)氨基)的各种多晶型和无定形形式。 苯甲酸盐,包括多晶型物A,多晶型物的混合物,其制备方法及其在含有它们的药物组合物中的用途。
-
4.
公开(公告)号:US20140275113A1
公开(公告)日:2014-09-18
申请号:US14208244
申请日:2014-03-13
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: C07D261/20
CPC分类号: A61K31/496 , A61K9/0053 , A61K45/06 , C07B2200/13 , C07D261/20 , Y02A50/414 , A61K2300/00
摘要: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
摘要翻译: 本发明涉及4 - ((3-(4-环己基哌嗪-1-基)-6-氧代-6H-蒽[1,9-cd]异恶唑-5-基)氨基)的各种多晶型和无定形形式。 苯甲酸盐,包括多晶型物A,多晶型物的混合物,其制备方法及其在含有它们的药物组合物中的用途。
-
公开(公告)号:US08809530B1
公开(公告)日:2014-08-19
申请号:US14256094
申请日:2014-04-18
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: A61K31/496 , A61P31/12 , A61P29/00 , A61P17/06 , A61K45/06 , C07D261/20 , C07D413/10
CPC分类号: C07D498/06 , A61K31/496 , A61K31/497 , A61K45/06 , C07D215/20 , C07D221/06 , C07D223/32 , C07D241/44 , C07D261/20 , C07D265/36 , C07D279/16 , C07D295/13 , C07D307/77 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D493/06 , C07D495/04 , C07D498/04 , C07D513/04
摘要: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF recptor TrkA.
摘要翻译: 本发明涉及新型合成取代的杂环化合物和含有能够抑制或拮抗受体酪氨酸激酶家族(Tropomysosin Related Kinases,Trk),特别是神经生长因子(NGF)受体TrkA的家族的合成取代的杂环化合物和药物组合物。 本发明还涉及这些化合物在治疗和/或预防疼痛,癌症,再狭窄,动脉粥样硬化,牛皮癣,血栓形成或与异常髓鞘或脱髓鞘有关的疾病,病症或损伤或与异常活动有关的疾病或病症 的NGF吸收器TrkA。
-
公开(公告)号:US20160002182A1
公开(公告)日:2016-01-07
申请号:US14772264
申请日:2014-03-14
申请人: VM PHARMA LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: C07D261/20 , A61K31/496
CPC分类号: A61K31/496 , A61K9/0053 , A61K45/06 , C07B2200/13 , C07D261/20 , Y02A50/414 , A61K2300/00
摘要: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
-
公开(公告)号:US20150218188A1
公开(公告)日:2015-08-06
申请号:US14685806
申请日:2015-04-14
申请人: VM Pharma LLC
发明人: Jay Jie-Qiang Wu , Ling Wang
IPC分类号: C07D498/06 , A61K45/06 , C07D413/12 , C07D493/06 , C07D407/12 , C07D261/20 , A61K31/496 , A61K31/497
CPC分类号: C07D498/06 , A61K31/496 , A61K31/497 , A61K45/06 , C07D215/20 , C07D221/06 , C07D223/32 , C07D241/44 , C07D261/20 , C07D265/36 , C07D279/16 , C07D295/13 , C07D307/77 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D493/06 , C07D495/04 , C07D498/04 , C07D513/04
摘要: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
摘要翻译: 本发明涉及新型合成取代的杂环化合物和含有能够抑制或拮抗受体酪氨酸激酶家族(Tropomysosin Related Kinases,Trk),特别是神经生长因子(NGF)受体TrkA的家族的合成取代的杂环化合物和药物组合物。 本发明还涉及这些化合物在治疗和/或预防疼痛,癌症,再狭窄,动脉粥样硬化,牛皮癣,血栓形成或与异常髓鞘或脱髓鞘有关的疾病,病症或损伤或与异常活动有关的疾病或病症 的NGF受体TrkA。
-
-
-
-
-
-